Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Fundamentals
Mkt Cap
$1.35B
Volume
-
52W High
$57.14
52W Low
$19.14
PE Ratio
-20.93
Avg. Volume
141,463.37
EPS (Annual)
-$0.5655
P/B
-35.27
Rev/Employee
$344,891.09
Earnings
Mar 30
50
Neutral Sentiment
How do you feel about NBTX?
focafoca99
$NBTX announced Phase 1 data showing 41.7% response rate and 17.8-month median OS in anti-PD-1-resistant melanoma, with acceptable safety.
Rayvio_News_Filter
$NBTX 🏥
Nanobiotix S.A. reported final Phase 1 data for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 heavily pretreated anti-PD-1-resistant primary cutaneous melanoma patients, showing an acceptable safety profile, 41.7% overall response rate, 4 complete responses, 75% disease control rate, and 17.8 months median overall survival.
Curated for market relevance
Link your Stocktwits account
Ask your agent for live sentiment, watchers, trending tickers, and news.